Spirinolactone versus Bicalatumide in female pattern hair loss

Spirinolactone versus Bicalatumide in female pattern hair loss; a randomised clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/062101

Enrollment

200

Registered

2024-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L648- Other androgenic alopecia

Interventions

Intervention1: Bicalatumide: Dose-50mg OD (Once daily) Duration-24 weeks Route of administration-Oral Control Intervention1: Spirinolactone: Dose-100mg OD (Once daily) Duration-24 weeks Route of admin

Eligibility

Inclusion criteria

Inclusion criteria: Treatment naive Grade 2-5 Female Pattern Hair loss

Exclusion criteria

Exclusion criteria: Nursing and pregnant females History of topical minoxidil application History of malignancy History of any SSRI, antihypertensive, potassium supplement Any other hormonal therapy, oral contraceptive pills

Design outcomes

Primary

Measure	Time frame
Increase in hair density in 200 patients Adverse effects in 200 patients Timepoint: 24 weeks	—

Secondary

Measure	Time frame
Increase in hair density in 200patients Averse effects in 200 patientsTimepoint: 4 weeks,8 weeks,12 weeks,16 weeks, 20 weeks	—

Countries

India

Contacts

Public ContactAbhijeet Kumar Jha

Patna Medical College

drabhijeetjha@gmail.com09631444797

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026